AbbVie and Xilio Therapeutics announce collaboration
AbbVie (ABBV) and Xilio Therapeutics (XLO) announced a collaboration and option-to-license agreement to develop novel tumor-activated, ...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
FiercePharma4d
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...
pharmaphorum1d
A history of Abbott and AbbVie
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
pharmaphorum1d
AbbVie gets bigger in Alzheimer's R&D with Aliada takeover
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...
Pharmaceutical Technology4d
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
Credit: Studio Romantic/Shutterstock. AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people ...
Yahoo Finance3d
AbbVie Inc. (ABBV)
Pre-Market: 4:16:55 a.m. EST ...